EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets

Zhiji Chen, Siqi Liao, Suhua Wu, Siyuan Chen, Qin Tang, Li Zhou, Xiaoqin Li, Huiyi Hu, Jiayao Xu, An Zhang, Song He, Zhi-Hang Zhou iD

MedComm · 2025-11 · 6 (11)

DOI: 10.1002/mco2.70458 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 11.11.2025. Verfasst von Zhiji Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology The Second Affiliated Hospital of Chongqing Medical University Chongqing China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 234 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increasing global burden of liver disease is a growing public health challenge. The gut‒liver axis, a bidirectional communication system between the intestine and liver via the portal circulation and biliary tract, is crucial for maintaining metabolic and immune homeostasis. Dysregulation of the gut‒liver axis has been recognized as a key driver of the pathogenesis of various liver diseases. However, its complex molecular mechanisms and the resulting precision therapeutic strategies remain under investigation. This review elaborates on the core components of the gut‒liver axis and the key mechanisms of gut‒liver axis imbalance in metabolic dysfunction‐associated fatty liver disease, alcohol‐associated liver disease, cirrhosis, spontaneous bacterial peritonitis, and primary liver cancer. We discuss the core roles of intestinal barrier dysfunction, dysbiosis, liver immune activation, and bacterial metabolite imbalance. Furthermore, we systematically review emerging therapeutic strategies targeting this axis, such as restoring barrier function, correcting dysbiosis, regulating bacterial metabolism, and blocking deleterious signaling. This review provides an integrative perspective on the pathophysiology of liver diseases and highlights the great potential of targeting the gut‒liver axis in translational medicine to improve the treatment paradigm for liver diseases.

Schlagwörter

Stichwörter der Autor:innen

dysbiosisgut–liver axisintestinal barrier dysfunctionliver diseasepathogenesis

Autor:innen und Institutionen

  • Department of Gastroenterology The Second Affiliated Hospital of Chongqing Medical University Chongqing China.
  • Department of Critical Care Medicine The Second Affiliated Hospital of Chongqing Medical University Chongqing China.

ORCID-Profile: Zhi-Hang Zhou

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, Z., Liao, S., Wu, S., Chen, S., Tang, Q., Zhou, L., Li, X., Hu, H., Xu, J., Zhang, A., He, S., & Zhou, Z. H. (2025). The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets. MedComm, 6(11). https://doi.org/10.1002/mco2.70458

Vancouver

Chen Z, Liao S, Wu S, Chen S, Tang Q, Zhou L, et al. The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets. MedComm. 2025;6(11). doi:10.1002/mco2.70458

BibTeX
@article{Chen2025,
  author = {Chen, Zhiji and Liao, Siqi and Wu, Suhua and Chen, Siyuan and Tang, Qin and Zhou, Li and Li, Xiaoqin and Hu, Huiyi and Xu, Jiayao and Zhang, An and He, Song and Zhou, Zhi-Hang},
  title = {The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {11},
  doi = {10.1002/mco2.70458}
}
Kostenlos starten →